Основная статистика
| CIK | 1578809 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Enzymotec Ltd.
SEC Filings (Chronological Order)
На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.
| February 13, 2018 |
ENZY / Enzymotec Ltd. / Phoenix Holdings Ltd. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Enzymotec Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.01 per share (Title of Class of Securities) M4059L101 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rul |
|
| February 13, 2018 |
ENZY / Enzymotec Ltd. / Phoenix Holdings Ltd. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* Enzymotec Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.01 per share (Title of Class of Securities) M4059L101 (CUSIP Number) February 6, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| January 31, 2018 |
ENZY / Enzymotec Ltd. / Yelin Lapidot Holdings Management Ltd. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3) Enzymotec Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.01 per share (Title of Class of Securities) M4059L101 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| January 22, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 001-36073 Enzymotec Ltd. (Exact name of registrant as specified in its char |
|
| January 11, 2018 |
As filed with the Securities and Exchange Commission on January 11, 2018 Registration No. |
|
| January 11, 2018 |
As filed with the Securities and Exchange Commission on January 11, 2018 Registration No. |
|
| January 11, 2018 |
As filed with the Securities and Exchange Commission on January 11, 2018 Registration No. |
|
| January 11, 2018 |
ENZY / Enzymotec Ltd. FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2018 Commission File Number: 001-36073 ENZYMOTEC LTD. (Translation of registrant?s name into English) Sagi 2000 Industrial Area P.O. Box 6 Migdal Ha?Emeq 2310001, Israel (Address of princi |
|
| January 11, 2018 |
ENZY / Enzymotec Ltd. / Frutarom Ltd Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* Enzymotec Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.01 per share (Title of Class of Securities) M4059L101 (CUSIP Number) Tali Mirsky, Adv. Global VP Legal Affairs & Corporate Secretary Frutarom Ltd., 25 Hashaish St., Haifa 2629183, Israel +9 |
|
| December 26, 2017 |
ENZY / Enzymotec Ltd. 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2017 Commission File Number: 001-36073 ENZYMOTEC LTD. (Translation of registrant ?s name into English) Sagi 2000 Industrial Area P.O. Box 6 Migdal Ha?Emeq 2310001, Israel (Address of prin |
|
| December 12, 2017 |
ENZYMOTEC shareholders approve proposed acquisition by FRUTAROM Exhibit 99.1 FOR IMMEDIATE RELEASE December 11, 2017 ENZYMOTEC shareholders approve proposed acquisition by FRUTAROM MIGDAL HA?EMEQ, ISRAEL, December 11, 2017 ? Enzymotec Ltd. (NASDAQ:ENZY) (?Enzymotec? or the ?Company?), a developer, manufacturer and marketer of innovative bio-active lipid ingredients and nutritional products, today announced that at Enzymotec?s annual and extraordinary general m |
|
| December 12, 2017 |
ENZY / Enzymotec Ltd. FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2017 Commission File Number: 001-36073 ENZYMOTEC LTD. (Translation of registrant?s name into English) Sagi 2000 Industrial Area P.O. Box 6 Migdal Ha?Emeq 2310001, Israel (Address of princ |
|
| November 17, 2017 |
Exhibit 99.1 ENZYMOTEC LTD. Sagi 2000 Industrial Area P.O. Box 6 Migdal Ha’Emek 2310001, Israel November 17, 2017 Dear Enzymotec Ltd. Shareholders: We cordially invite you to attend the 2017 annual and extraordinary general meeting of shareholders of Enzymotec Ltd. (“Enzymotec,” the “Company” or “we”) to be held at the principal business office of Enzymotec, located at Sagi 2000 Industrial Area, M |
|
| November 17, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2017 Commission File Number: 001-36073 ENZYMOTEC LTD. (Translation of registrant’s name into English) Sagi 2000 Industrial Area P.O. Box 6 Migdal Ha’Emeq 2310001, Israel (Address of princ |
|
| November 17, 2017 |
Exhibit 99.2 ENZYMOTEC LTD. PROXY FOR 2017 ANNUAL AND EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON DECEMBER 11, 2017 THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS The undersigned hereby constitutes and appoints Dror Israel and Ron Mosberg, and each of them, the true and lawful attorneys, agents and proxies of the undersigned, with full power of substitution to each of |
|
| November 15, 2017 |
Enzymotec Ltd. Reports Third Quarter 2017 Unaudited Financial Results Exhibit 99.1 Enzymotec Ltd. Reports Third Quarter 2017 Unaudited Financial Results MIGDAL HA?EMEQ, Israel, November 15, 2017 ? Enzymotec Ltd. (Nasdaq: ENZY), a developer, manufacturer and marketer of innovative bio-active lipid ingredients and nutritional products, today reported financial results for the third quarter ended September 30, 2017. Third Quarter 2017 Results For the third quarter of 2 |
|
| November 15, 2017 |
ENZY / Enzymotec Ltd. 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2017 Commission File Number: 001-36073 ENZYMOTEC LTD. (Translation of registrant?s name into English) Sagi 2000 Industrial Area P.O. Box 6 Migdal Ha?Emeq 2310001, Israel (Address of princ |
|
| November 2, 2017 |
Enzymotec FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2017 Commission File Number: 001-36073 Enzymotec Ltd. (Translation of registrant?s name into English) Sagi 2000 Industrial Area P.O. Box 6 Migdal Ha?Emeq 2310001, Israel (Address of princ |
|
| November 2, 2017 |
Exhibit 99.1 Enzymotec Ltd. Calls 2017 Annual and Extraordinary General Meeting of Shareholders for Approval of Merger and Other Matters MIGDAL HA?EMEQ, ISRAEL, November 2, 2017?(GLOBENEWSWIRE)?Enzymotec Ltd. (NASDAQ: ENZY) (the ?Company?), today announced that it will hold its 2017 Annual and Extraordinary General Meeting of Shareholders (the ?Meeting?) on Monday, December 11, 2017 at 5:00 p.m. ( |
|
| October 30, 2017 |
Exhibit 99.1 AGREEMENT AND PLAN OF MERGER by and among FRUTAROM LTD. FRUTAROM TECH LTD. and ENZYMOTEC October 28, 2017 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS & INTERPRETATIONS - 1 - Section 1.1 Certain Definitions - 1 - Section 1.2 Additional Definitions - 9 - Section 1.3 Certain Interpretations - 11 - ARTICLE II THE MERGER - 12 - Section 2.1 The Merger - 12 - Section 2.2 The Closing - 12 - |
|
| October 30, 2017 |
Enzymotec 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2017 Commission File Number: 001-36073 ENZYMOTEC LTD. (Translation of registrant?s name into English) Sagi 2000 Industrial Area P.O. Box 6 Migdal Ha?Emeq 2310001, Israel (Address of princi |
|
| October 30, 2017 |
Enzymotec Enters Definitive Agreement to be Acquired by Frutarom Exhibit 99.2 Enzymotec Enters Definitive Agreement to be Acquired by Frutarom MIGDAL HA?EMEQ, Israel, Oct. 29, 2017 (GLOBE NEWSWIRE) - Enzymotec Ltd. (Nasdaq: ENZY), a developer, manufacturer and marketer of innovative bio-active lipid ingredients and nutritional products, today announced that it has signed a definitive agreement under which Frutarom, an Israeli company (LSE and TASE: FRUT), will |
|
| October 30, 2017 |
Exhibit 99.5 Frutarom Will Acquire Full Ownership of the Specialty Nutrition Company Enzymotec at a Net Investment of Approx. USD 210M FRUTAROM CONTINUES TO ESTABLISH ITSELF AS ONE OF THE WORLD’S TEN TOP COMPANIES IN ITS FIELD AND ANNOUNCES ITS NINTH ACQUISITION IN 2017 FOLLOWING ITS ACCELERATED INTERNAL GROWTH AND ACQUISITIONS MADE UNTIL NOW, FRUTAROM’S ANNUAL SALES RUN-RATE ALREADY REACHES CLOSE |
|
| October 30, 2017 |
ENZY / Enzymotec Ltd. / Frutarom Ltd Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* Enzymotec Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.01 per share (Title of Class of Securities) M4059L101 (CUSIP Number) Tali Mirsky, Adv. Global VP Legal Affairs & Corporate Secretary Frutarom Ltd., 25 Hashaish St., Haifa 2629183, Israel +9 |
|
| October 30, 2017 |
Exhibit 99.4 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER by and among FRUTAROM LTD. FRUTAROM TECH LTD. and ENZYMOTEC October 28, 2017 TABLE OF CONTENTS Page Article I DEFINITIONS & INTERPRETATIONS - 1 - Section 1.1 Certain Definitions - 1 - Section 1.2 Additional Definitions - 9 - Section 1.3 Certain Interpretations - 11 - Article II THE MERGER - 12 - Section 2.1 The Merger - 12 - Section 2.2 T |
|
| September 25, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (RULE 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(D)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 ENZYMOTEC LTD. (Name of Subject Company) ENZYMOTEC LTD. (Names of Persons Filing Statement) Ordinary Shares, par value NIS 0.01 per share (Title of Class of Securities) M4059L101 (CUSIP Number of Cl |
|
| September 18, 2017 |
ENZY / Enzymotec Ltd. / Frutarom Ltd Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Enzymotec Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.01 per share (Title of Class of Securities) M4059L101 (CUSIP Number) Tali Mirsky, Adv. Global VP Legal Affairs & Corporate Secretary Frutarom Ltd., 25 Hashaish St., Haifa 2629183, Israel +9 |
|
| September 18, 2017 |
SC TO-C 1 c89383sctoc.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 Enzymotec Ltd. (Name of Subject Company) Frutarom Ltd. (Name of Filing Persons (offerors)) Ordinary Shares, par value NIS 0.01 per share (Title of Class of Securities) M4059L101 (CUSIP Number o |
|
| September 18, 2017 |
EX-99.3 2 c89382ex99-3.htm Exhibit 99.3 September 18, 2017 Enzymotec Ltd. Sagi 2000 Industrial Area P.O. Box 6 Migdal Ha’Emeq 2310001, Israel Attention: Mr. Steve Dubin and the Board of Directors Ladies and Gentlemen: On behalf of Frutarom Ltd., I write to formally respond to your letter of August 28th. We appreciate your willingness to evaluate our interest in Enzymotec and to engage with us in r |
|
| September 18, 2017 |
Exhibit 99.2 Below is the immediate report submitted today to the Israeli Securities Authority (“ISA”) and the Tel-Aviv Stock Exchange through the ISA’s electronic submission system in accordance with the Securities Regulations (Periodic and Immediate Reports), 1970. Frutarom Industries Ltd. Registration No.: 52-004280-5 The securities of Frutarom Industries Ltd. are listed for trading on the Tel- |
|
| September 18, 2017 |
Exhibit 99.1 September 18, 2017 Enzymotec Ltd. Sagi 2000 Industrial Area P.O. Box 6 Migdal Ha’Emeq 2310001, Israel Attention: Mr. Steve Dubin and the Board of Directors Ladies and Gentlemen: On behalf of Frutarom Ltd., I write to formally respond to your letter of August 28th. We appreciate your willingness to evaluate our interest in Enzymotec and to engage with us in regards to discussing a mutu |
|
| September 11, 2017 |
ENZY / Enzymotec Ltd. / PAULSON & CO. INC. - SEPTEMBER 11, 2017 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (RULE 13d - 102) Under the Securities Exchange Act of 1934 (Amendment No. 4)* Enzymotec Ltd. (Name of Issuer) Ordinary Shares, par value NIS$0.01 per share (Title of Class of Securities) M4059L101 (CUSIP Number) August 23, 2017 (Date of Event which Requires Filing of this Statement) Check the appropriate box to de |
|
| August 30, 2017 |
EX-99.1 2 exhibit99-1.htm EXHIBIT 99.1 Exhbit 99.1 FOR IMMEDIATE RELEASE Enzymotec Ltd. Expands VAYA Product Portfolio with Five Nutritional Supplements Acquired from Union Springs Healthcare Roger Griggs, Acclaimed Health Care Entrepreneur, Becomes Senior Advisor to Help Grow Sales Channels MIGDAL HA'EMEQ, Israel, August 30, 2017 – Enzymotec Ltd. (Nasdaq: ENZY), a developer, manufacturer and mark |
|
| August 30, 2017 |
Enzymotec 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2017 Commission File Number: 001-36073 ENZYMOTEC LTD. (Translation of registrant?s name into English) Sagi 2000 Industrial Area P.O. Box 6 Migdal Ha?Emeq 2310001, Israel (Address of princip |
|
| August 28, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (RULE 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(D)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 ENZYMOTEC LTD. (Name of Subject Company) ENZYMOTEC LTD. (Names of Persons Filing Statement) Ordinary Shares, par value NIS 0.01 per share (Title of Class of Securities) M4059L101 (CUSIP Number of Cl |
|
| August 28, 2017 |
Enzymotec Responds to Unsolicited Proposal from Frutarom Exhibit 99.1 Enzymotec Responds to Unsolicited Proposal from Frutarom MIGDAL HA'EMEQ, Israel, Aug. 28, 2017 (GLOBE NEWSWIRE) - Enzymotec Ltd. (Nasdaq: ENZY) today responded to the unsolicited proposal from Frutarom Ltd. to acquire Enzymotec for $11.50 per share by sending the below letter to Frutarom Chief Executive Officer, Ori Yehudai. Frutarom has not, as of the date of this press release, laun |
|
| August 28, 2017 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 Enzymotec Ltd. (Name of Subject Company) Frutarom Ltd. (Name of Filing Persons (offerors)) ORDINARY SHARES, PAR VALUE NIS $0.01 PER SHARE (Title of Class of Securities) M4059L101 (CUSIP Number of Class of Securities) Tali Mirsky Glob |
|
| August 28, 2017 |
Paulson’s huge losses paved the way to Frutarom’s takeover of Enzymotec Exhibit 99.1 SMELL OF TAKEOVER Frutarom increased its holdings in Enzymotec to 19% and announced its intention to issue a full tender offer. Ori Yehudai: “We won’t stay in Enzymotec if we can’t lead the way to a new strategy.” Paulson’s huge losses paved the way to Frutarom’s takeover of Enzymotec Frutarom bought 9.2% of Enzymotec from billionaire John Paulson’s investment firm and announced its i |
|
| August 24, 2017 |
ENZY / Enzymotec Ltd. / Frutarom Ltd Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Enzymotec Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.01 per share (Title of Class of Securities) M4059L101 (CUSIP Number) Tali Mirsky Global VP Legal Affairs & Corporate Secretary Frutarom Ltd., 25 Hashaish St., Haifa 2629183, Israel +9729960 |
|
| August 24, 2017 |
Frutarom set to acquire control of Enzymotec Exhibit 99.1 Frutarom set to acquire control of Enzymotec Frutarom plans to publish an offer to purchase for the rest of the shares it does not already own. Frutarom Industries Ltd. (TASE: FRUT; LSE:FRUT; Bulletin Board: FRUTF), which makes raw materials and flavors for the global food and beverages industry, is in the process of completing a takeover of Israeli company Enzymotec Ltd. (Nasdaq: ENZ |
|
| August 24, 2017 |
Exhibit 99.2 EXECUTION COPY Tender and Support Agreement This Tender and Support Agreement, dated as of August 23, 2017 (this “Agreement”), is between Frutarom Ltd., an Israeli corporation (“Frutarom”), and Paulson & Co. Inc., a Delaware corporation, on behalf of funds and accounts managed by it (the “Stockholder”). A. In connection with the execution and delivery of this Agreement, Frutarom shall |
|
| August 24, 2017 |
Exhibit 99.1 August 24, 2017 FRUTAROM BOUGHT A 9.2% STAKE FROM PAULSON, ENZYMOTEC’S LARGEST SHAREHOLDER, TO REACH A 19.1% STAKE IN ENZYMOTEC ANNOUNCES ITS INTENTION TO MAKE A FULL TENDER OFFER TO ACQUIRE THE REMAINING SHARES OF ENZYMOTEC PAULSON AGREED TO SUPPORT THE TENDER OFFER AND SELL IN THAT FRAMEWORK ITS REMAINING 9.2% STAKE IN ENZYMOTEC Herzliya, Israel Frutarom Industries Ltd. (“Frutarom” |
|
| August 24, 2017 |
SC TO-C 1 c89252sctoc.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 Enzymotec Ltd. (Name of Subject Company) Frutarom Ltd. (Name of Filing Persons (offerors)) ORDINARY SHARES, PAR VALUE NIS $0.01 PER SHARE (Title of Class of Securities) M4059L101 (CUSIP Number of Class of Se |
|
| August 24, 2017 |
EX-99.2 5 c89252ex99-2.htm Exhibit 99.2 Below is the immediate report submitted today to the Israeli Securities Authority (“ISA”) and the Tel-Aviv Stock Exchange through the ISA’s electronic submission system in accordance with the Securities Regulations (Periodic and Immediate Reports), 1970. Frutarom Industries Ltd. Registration No.: 52-004280-5 The securities of Frutarom Industries Ltd. are lis |
|
| August 24, 2017 |
EX-99.1 2 c89252ex99-1.htm Exhibit 99.1 August 24, 2017 FRUTAROM BOUGHT A 9.2% STAKE FROM PAULSON, ENZYMOTEC’S LARGEST SHAREHOLDER, TO REACH A 19.1% STAKE IN ENZYMOTEC ANNOUNCES ITS INTENTION TO MAKE A FULL TENDER OFFER TO ACQUIRE THE REMAINING SHARES OF ENZYMOTEC PAULSON AGREED TO SUPPORT THE TENDER OFFER AND SELL IN THAT FRAMEWORK ITS REMAINING 9.2% STAKE IN ENZYMOTEC Herzliya, Israel Frutarom I |
|
| August 24, 2017 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 Enzymotec Ltd. (Name of Subject Company) Frutarom Ltd. (Name of Filing Persons (offerors)) ORDINARY SHARES, PAR VALUE NIS $0.01 PER SHARE (Title of Class of Securities) M4059L101 (CUSIP Number of Class of Securities) Tali Mirsky Glob |
|
| August 16, 2017 |
Exhibit 99.1 Enzymotec Ltd. Reports Second Quarter 2017 Unaudited Financial Results Record INFAT® Net Revenues of $13.3 Million (Proportionate Consolidation Method) Generated Strong Cash Flow from Operations of $2.9 Million Inventory Write-Off of $3.3 Million MIGDAL HA'EMEQ, Israel, August 16, 2017 – Enzymotec Ltd. (Nasdaq: ENZY), a developer, manufacturer and marketer of innovative bio-active lip |
|
| August 16, 2017 |
Enzymotec 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2017 Commission File Number: 001-36073 ENZYMOTEC LTD. (Translation of registrant?s name into English) Sagi 2000 Industrial Area P.O. Box 6 Migdal Ha?Emeq 2310001, Israel (Address of princip |
|
| August 10, 2017 |
Notice of resolution of the Board of Directors of Delek Group Ltd., dated as of November 25, 2009. Exhibit 2 Delek Group Ltd 25/11/2009 Re: Delek Group Ltd (hereinafter: "The Company") I hereby confirm that according to the board of directors' resolution, the company's signature rights, effective these date are as follows: The joint signatures of any two signatories listed below, on and above the company seal or printed name, bind the company for any purpose. |
|
| August 10, 2017 |
Agreement of Joint Filing by and among the Reporting Persons, dated as of August 09, 2017. Exhibit 1 JOINT FILING AGREEMENT Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of shares of Enzymotec Ltd. |
|
| August 10, 2017 |
ENZY / Enzymotec Ltd. / Phoenix Holdings Ltd. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Enzymotec Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.01 per share (Title of Class of Securities) M4059L101 (CUSIP Number) June 22, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pur |
|
| August 10, 2017 |
Exhibit 3 [Unofficial Translation] May 25, 2017 Powers of Signature in The Phoenix Holdings Ltd. |
|
| August 3, 2017 |
ENZY / Enzymotec Ltd. / Frutarom Ltd Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Enzymotec Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.01 per share (Title of Class of Securities) M4059L101 (CUSIP Number) Tali Mirsky Global VP Legal Affairs & Corporate Secretary Frutarom Ltd., 25 Hashaish St., Haifa 2629183, Israel +9729960 |
|
| July 31, 2017 |
ENZY / Enzymotec Ltd. / Frutarom Ltd Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Enzymotec Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.01 per share (Title of Class of Securities) M4059L101 (CUSIP Number) Tali Mirsky Global VP Legal Affairs & Corporate Secretary Frutarom Ltd., 25 Hashaish St., Haifa 2629183, Israel +97299603800 (Name, Address |
|
| July 28, 2017 |
Enzymotec 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of July 2017 Commission File Number: 001-36073 ENZYMOTEC LTD. (Translation of registrant?s name into English) Sagi 2000 Industrial Area P.O. Box 6 Migdal Ha?Emeq 2310001, Israel (Address of princi |
|
| July 28, 2017 |
Enzymotec Ltd. Announces Appointment of Dror Israel as Chief Financial Officer EX-99.1 2 exhibit99-1.htm EXHIBIT 99.1 Exhibit 99.1 Enzymotec Ltd. Announces Appointment of Dror Israel as Chief Financial Officer MIGDAL HA'EMEQ, Israel, July 28, 2017 (GLOBE NEWSWIRE) - Enzymotec Ltd. (Nasdaq:ENZY) ("Enzymotec" or the "Company"), a developer, manufacturer and marketer of innovative bio-active lipid based nutritional ingredients and medical foods, today announced that Mr. Dror Is |
|
| July 17, 2017 |
EXHIBIT 1 JOINT FILING AGREEMENT In accordance with the requirements of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and subject to the limitations set forth therein, the parties set forth below agree to jointly file the Schedule 13G to which this joint filing agreement is attached, and have duly executed this joint filing agreement as of the date set forth below. |
|
| July 17, 2017 |
Enzymotec SC 13G (Passive Acquisition of More Than 5% of Shares) SC 13G 1 zk1720239.htm SC 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2* Enzymotec Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.01 per share (Title of Class of Securities) M4059L101 (CUSIP Number) April 5, |
|
| July 17, 2017 |
Enzymotec SC 13G/A (Passive Acquisition of More Than 5% of Shares) zk1516232.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2 (Amendment No. 1)* Enzymotec Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.01 per share (Title of Class of Securities) M4059L101 (CUSIP Number) April 5 |
|
| July 17, 2017 |
EXHIBIT 1 JOINT FILING AGREEMENT In accordance with the requirements of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and subject to the limitations set forth therein, the parties set forth below agree to jointly file Amendment No. |
|
| June 28, 2017 |
Enzymotec 6-K (Current Report of Foreign Issuer) SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2017 Commission File Number: 001-36073 Enzymotec Ltd. (Translation of registrant?s name into English) Sagi 2000 Industrial Area P.O. Box 6 Migdal Ha?Emeq 2310001, Israel (Address of principal executive off |
|
| June 28, 2017 |
Exhibit 99.1 Enzymotec Chief Financial Officer to Step Down Oren Bryan to leave his position after 9 years of service to Enzymotec MIGDAL HA'EMEQ, Israel, June 28, 2017 ? Enzymotec Ltd. (Nasdaq: ENZY) (?Enzymotec? or the ?Company?), a developer, manufacturer and marketer of innovative bio-active lipid ingredients and medical foods, today announced that Mr. Oren Bryan, will be stepping down from hi |
|
| May 17, 2017 |
Enzymotec 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of May 2017 Commission File Number: 001-36073 ENZYMOTEC LTD. (Translation of registrant?s name into English) Sagi 2000 Industrial Area P.O. Box 6 Migdal Ha?Emeq 2310001, Israel (Address of princip |
|
| May 17, 2017 |
Enzymotec Ltd. Reports First Quarter 2017 Unaudited Financial Results Exhibit 99.1 Enzymotec Ltd. Reports First Quarter 2017 Unaudited Financial Results MIGDAL HA'EMEQ, Israel, May 17, 2017 ? Enzymotec Ltd. (Nasdaq: ENZY), a developer, manufacturer and marketer of innovative bio-active lipid ingredients and medical foods, today reported financial results for the first quarter ended March 31, 2017. First Quarter 2017 Financial Highlights ? First quarter net revenues |
|
| May 10, 2017 |
Enzymotec 6-K (Current Report of Foreign Issuer) 6-K 1 zk1719930.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of May 2017 Commission File Number: 001-36073 ENZYMOTEC LTD. (Translation of registrant’s name into English) Sagi 2000 Industrial Area P.O. Box 6 Migdal Ha’Emeq 2310001, Is |
|
| April 26, 2017 |
Enzymotec 6-K (Current Report of Foreign Issuer) SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2017 Commission File Number: 001-36073 Enzymotec Ltd. (Translation of registrant?s name into English) Sagi 2000 Industrial Area P.O. Box 6 Migdal Ha?Emeq 2310001, Israel (Address of principal executive of |
|
| April 3, 2017 |
EX-99.1 2 exhibit99-1.htm EXHIBIT 99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Neptune and Enzymotec reach Patent Agreement Ending All Litigation Both Parties Recognize Respective Company’s Patent Strength Laval, Québec, CANADA and Migdal Ha’Emeq, ISRAEL – March 30, 2017 – Neptune Technologies & Bioressources Inc. (“Neptune”) (NASDAQ: NEPT and TSX: NEPT) and Enzymotec Ltd., Enzymotec USA, Inc. (togethe |
|
| April 3, 2017 |
Enzymotec 6-K (Current Report of Foreign Issuer) 6-K 1 zk1719782.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of April 2017 Commission File Number: 001-36073 ENZYMOTEC LTD. (Translation of registrant’s name into English) Sagi 2000 Industrial Area P.O. Box 6 Migdal Ha’Emeq 2310001, |
|
| March 16, 2017 |
Exhibit 99.2 ENZYMOTEC LTD. PROXY FOR THE EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON APRIL 25, 2017 THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS The undersigned hereby constitutes and appoints Oren Bryan and Ron Mosberg, and each of them, the true and lawful attorneys, agents and proxies of the undersigned, with full power of substitution to each of them, to represe |
|
| March 16, 2017 |
Enzymotec 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2017 Commission File Number: 001-36073 ENZYMOTEC LTD. (Translation of registrant's name into English) Sagi 2000 Industrial Area P.O. Box 6 Migdal Ha'Emeq 2310001, Israel (Address of principa |
|
| March 16, 2017 |
ENZYMOTEC LTD. Sagi 2000 Industrial Area P.O. Box 6 Migdal Ha'Emek 2310001, Israel Exhibit 99.1 ENZYMOTEC LTD. Sagi 2000 Industrial Area P.O. Box 6 Migdal Ha'Emek 2310001, Israel March 16, 2017 Dear Enzymotec Ltd. Shareholder: We cordially invite you to attend an extraordinary general meeting of shareholders, or the Meeting, of Enzymotec Ltd., or the Company, to be held at 10:00 a.m. (Israel time) on Tuesday, April 25, 2017, at our offices at Sagi 2000 Industrial Area, Migdal Ha |
|
| March 16, 2017 |
S-8 1 zk1719686.htm S-8 As filed with the Securities and Exchange Commission on March 16, 2017 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ENZYMOTEC LTD. (Exact name of registrant as specified in its charter) Israel Not Applicable (State or Other Jurisdiction of (I.R.S. Employer Incor |
|
| March 16, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EX |
|
| March 16, 2017 |
EXHIBIT 13.1 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Enzymotec Ltd. (the “Company”) on Form 20-F for the period ended December 31, 2016, as filed with the Securities and Exchange Commission on the date hereof (the “Repo |
|
| March 16, 2017 |
EXHIBIT 12.1 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO EXCHANGE ACT RULE 13A-14(A)/15D-14(A) AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Ariel Katz, certify that: 1. I have reviewed this annual report on Form 20-F of Enzymotec Ltd. (the “company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to st |
|
| March 16, 2017 |
EXHIBIT 12.2 CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO EXCHANGE ACT RULE 13A-14(A)/15D-14(A) AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Oren Bryan, certify that: 1. I have reviewed this annual report on Form 20-F of Enzymotec Ltd. (the “company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to st |
|
| March 16, 2017 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM EXHIBIT 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-193118 and 333-202839 ) of Enzymotec Ltd. of our report dated March 16, 2017 relating to the consolidated financial statements of Enzymotec Ltd., which appears in this Form 20-F. Tel-Aviv, Israel /s/ Kesselman & Kesselman Mar |
|
| March 10, 2017 |
Enzymotec Ltd. Calls an Extraordinary General Meeting of Shareholders Exhibit 99.1 Enzymotec Ltd. Calls an Extraordinary General Meeting of Shareholders MIGDAL HA?EMEQ, ISRAEL, March 10, 2017?(GLOBENEWSWIRE)?Enzymotec Ltd. (NASDAQ: ENZY) (the ?Company?), today announced that it will hold an Extraordinary General Meeting of Shareholders (the ?Meeting?) at 10:00 am local time on Tuesday, April 25, 2017 at the Company?s offices, at Sagi 2000 Industrial Area, Migdal Ha? |
|
| March 10, 2017 |
Enzymotec 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2017 Commission File Number: 001-36073 ENZYMOTEC LTD. (Translation of registrant?s name into English) Sagi 2000 Industrial Area P.O. Box 6 Migdal Ha?Emeq 2310001, Israel (Address of principa |
|
| March 9, 2017 |
Enzymotec 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of March 2017 Commission File Number: 001-36073 ENZYMOTEC LTD. (Translation of registrant?s name into English) Sagi 2000 Industrial Area P.O. Box 6 Migdal Ha?Emeq 2310001, Israel (Address of princ |
|
| March 9, 2017 |
Enzymotec Ltd. Announces the Appointment of Erez Israeli as President and CEO Exhibit 99.1 Enzymotec Ltd. Announces the Appointment of Erez Israeli as President and CEO MIGDAL HA'EMEQ, Israel, March 09, 2017 (GLOBE NEWSWIRE) - Enzymotec Ltd. (Nasdaq:ENZY) ("Enzymotec" or the "Company"), a developer, manufacturer and marketer of innovative bio-active lipid based nutritional ingredients and medical foods, today announced that its Board of Directors has appointed Erez Israeli |
|
| March 2, 2017 |
Enzymotec Ltd. Reports Fourth Quarter and Full Year 2016 Unaudited Financial Results Exhibit 99.1 Enzymotec Ltd. Reports Fourth Quarter and Full Year 2016 Unaudited Financial Results MIGDAL HA'EMEQ, Israel, February 22, 2017 ? Enzymotec Ltd. (Nasdaq: ENZY), a developer, manufacturer and marketer of innovative bio-active lipid ingredients and medical foods, today reported financial results for the fourth quarter and full year ended December 31, 2016. Fourth Quarter 2016 Financial a |
|
| March 2, 2017 |
Enzymotec 6-K (Current Report of Foreign Issuer) 6-K 1 zk1719632.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of March 2017 Commission File Number: 001-36073 ENZYMOTEC LTD. (Translation of registrant's name into English) Sagi 2000 Industrial Area P.O. Box 6 Migdal Ha'Emeq 2310001, |
|
| February 15, 2017 |
ENZY / Enzymotec Ltd. / Visium Asset Management, LP - AMENDED SC 13G Passive Investment SC 13G/A 1 enzy123116.htm AMENDED SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Enzymotec Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.01 per share (Title of Class of Securities) M4059L101 (CUSIP Number) December 31, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropria |
|
| February 14, 2017 |
ENZY / Enzymotec Ltd. / PAULSON & CO. INC. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Enzymotec Ltd. (Name of Issuer) Ordinary Shares, par value NIS$0.01 per share (Title of Class of Securities) M4059L101 (CUSIP Number) December 31, 2016 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rul |
|
| February 13, 2017 |
ENZY / Enzymotec Ltd. / Yelin Lapidot Holdings Management Ltd. - SC 13G/A Passive Investment SC 13G/A 1 zk1719511.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2) Enzymotec Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.01 per share (Title of Class of Securities) M4059L101 (CUSIP Number) December 31, 2016 (1) (Date of Event Which Requires Filing of this Statement) Check the |
|
| February 8, 2017 |
ENZY / Enzymotec Ltd. / Yelin Lapidot Holdings Management Ltd. - SC 13G/A Passive Investment SC 13G/A 1 zk1719500.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) Enzymotec Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.01 per share (Title of Class of Securities) M4059L101 (CUSIP Number) December 31, 2016 (Date of Event Which Requires Filing of this Statement) Check the app |
|
| February 6, 2017 |
Enzymotec 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of February 2017 Commission File Number: 001-36073 ENZYMOTEC LTD. (Translation of registrant's name into English) Sagi 2000 Industrial Area P.O. Box 6 Migdal Ha'Emeq 2310001, Israel (Address of pr |
|
| February 6, 2017 |
Exhibit 99.1 Enzymotec Ltd. Announces Preliminary Fourth Quarter and Full Year 2016 Financial Results $2.0 million inventory write-off impacts GAAP and non-GAAP EPS by ($0.09) $0.9 million bad debt provision impacts GAAP EPS by ($0.04) MIGDAL HA'EMEQ, Israel, February 6, 2017 (GLOBE NEWSWIRE) - Enzymotec Ltd. (Nasdaq: ENZY) ("Enzymotec" or the "Company"), a developer, manufacturer and marketer of |
|
| November 16, 2016 |
Exhibit 99.1 Enzymotec Ltd. Reports Third Quarter 2016 Unaudited Financial Results Nutrition Segment increased Adjusted EBITDA* to $4M, representing 27% year-over-year and 17% sequential growth VAYA Pharma sales to patients grew 45% year-over-year, but inventory destocking by wholesalers driven by the rapid adoption of VAYA?s online pharmacy negatively impacts EPS b y $0.05 MIGDAL HA'EMEQ, Israel, |
|
| November 16, 2016 |
Enzymotec 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of November 2016 Commission File Number: 001-36073 ENZYMOTEC LTD. (Translation of registrant?s name into English) Sagi 2000 Industrial Area P.O. Box 6 Migdal Ha?Emeq 2310001, Israel (Address of pr |
|
| November 16, 2016 |
Enzymotec Ltd. Announces Departure of its CEO Exhibit 99.2 Enzymotec Ltd. Announces Departure of its CEO MIGDAL HA'EMEQ, Israel, November 16, 2016 (GLOBE NEWSWIRE) - Enzymotec Ltd. (Nasdaq:ENZY) ("Enzymotec" or the "Company"), a developer, manufacturer and marketer of innovative bio-active lipid based nutritional ingredients and medical foods, today announced that Dr. Ariel Katz, the Company’s President and Chief Executive Officer, will depar |
|
| August 25, 2016 |
Enzymotec 6-K (Current Report of Foreign Issuer) SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2016 Commission File Number: 001-36073 Enzymotec Ltd. (Translation of registrant’s name into English) Sagi 2000 Industrial Area P.O. Box 6 Migdal Ha’Emeq 2310001, Israel (Address of principal executive o |
|
| August 25, 2016 |
Enzymotec 6-K (Current Report of Foreign Issuer) SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2016 Commission File Number: 001-36073 Enzymotec Ltd. (Translation of registrant’s name into English) Sagi 2000 Industrial Area P.O. Box 6 Migdal Ha’Emeq 2310001, Israel (Address of principal executive o |
|
| August 11, 2016 |
Enzymotec 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of August 2016 Commission File Number: 001-36073 ENZYMOTEC LTD. (Translation of registrant’s name into English) Sagi 2000 Industrial Area P.O. Box 6 Migdal Ha’Emeq 2310001, Israel (Address of prin |
|
| August 11, 2016 |
Exhibit 99.1 Enzymotec Ltd. Reports Second Quarter 2016 Unaudited Financial Results VAYA Pharma Generated Record Net Revenues of $3.4 Million GAAP Diluted EPS Impacted by Decline in the Krill Oil Revenues Two U.S. Based Multinationals and Other Large Manufacturers Launched Infant Formula Containing INFAT® at CBME China MIGDAL HA'EMEQ, Israel, August 9, 2016 – Enzymotec Ltd. (Nasdaq: ENZY), a devel |
|
| July 25, 2016 |
Enzymotec 6-K (Current Report of Foreign Issuer) 6-K 1 zk1618763.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2016 Commission File Number: 001-36073 ENZYMOTEC LTD. (Translation of registrant’s name into English) Sagi 2000 Industrial Area P.O. Box 6 Migdal Ha’Emeq 2310001, Isra |
|
| July 25, 2016 |
EX-99.2 3 exhibit99-2.htm EXHIBIT 99.1 Exhibit 99.2 ENZYMOTEC LTD. PROXY FOR THE 2016 ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON AUGUST 25, 2016 THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS The undersigned hereby constitutes and appoints Oren Bryan and Ron Mosberg, and each of them, the true and lawful attorneys, agents and proxies of the undersigned, with full power of su |
|
| July 25, 2016 |
ENZYMOTEC LTD. Sagi 2000 Industrial Area P.O. Box 6 Migdal Ha’Emek 2310001, Israel Exhibit 99.1 ENZYMOTEC LTD. Sagi 2000 Industrial Area P.O. Box 6 Migdal Ha?Emek 2310001, Israel July 25, 2016 Dear Enzymotec Ltd. Shareholder: We cordially invite you to attend the 2016 annual general meeting of shareholders, or the Meeting, of Enzymotec Ltd., or the Company, to be held at 5:00 p.m. (Israel time) on Thursday, August 25, 2016, at our offices at Sagi 2000 Industrial Area, Migdal Ha? |
|
| July 25, 2016 |
Exhibit 1 Joint Filing Agreement Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of shares of Enzymotec Ltd. |
|
| July 25, 2016 |
ENZY / Enzymotec Ltd. / Yelin Lapidot Holdings Management Ltd. - SC 13G Passive Investment SC 13G 1 zk1618762.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Enzymotec Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.01 per share (Title of Class of Securities) M4059L101 (CUSIP Number) December 31, 2015 (1) (Date of Event Which Requires Filing of this Statement) Check the appr |
|
| July 14, 2016 |
Enzymotec 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _ FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2016 Commission File Number: 001-36073 ENZYMOTEC LTD. (Translation of registrant’s name into English) Sagi 2000 Industrial Area P.O. Box 6 Migdal Ha’Emeq 2310001, Israel (Address of princip |
|
| July 1, 2016 |
ENZY / Enzymotec Ltd. / TIGER MANAGEMENT L.L.C. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| May 19, 2016 |
Enzymotec 6-K (Current Report of Foreign Issuer) 6-K 1 zk1618541.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of May 2016 Commission File Number: 001-36073 ENZYMOTEC LTD. (Translation of registrant’s name into English) Sagi 2000 Industrial Area P.O. Box 6 Migdal Ha’Emeq 2310001, Is |
|
| May 19, 2016 |
exhibit99-1.htm Exhibit 99.1 Enzymotec Ltd. Reports First Quarter 2016 Unaudited Financial Results Reports Net Revenues of $14.0 Million, Earns $0.09 Per Diluted Share (non-GAAP) and Generates $3.3 Million in Operating Cash Flow VAYA Pharma Generates Record Net Revenues of $3.1 Million MIGDAL HA'EMEQ, Israel, May 19, 2016 ? Enzymotec Ltd. (Nasdaq: ENZY), a developer, manufacturer and marketer of i |
|
| May 16, 2016 |
Enzymotec 6-K (Current Report of Foreign Issuer) zk1618509.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2016 Commission File Number: 001-36073 Enzymotec Ltd. (Translation of registrant’s name into English) Sagi 2000 Industrial Area P.O. Box 6 Migdal Ha’Emeq 2310001, Israel (Address of principal |
|
| March 15, 2016 |
Enzymotec 6-K (Current Report of Foreign Issuer) 6-K 1 zk1618208.htm 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2016 Commission File Number: 001-36073 Enzymotec Ltd. (Translation of registrant’s name into English) Sagi 2000 Industrial Area P.O. Box 6 Migdal Ha’Emeq 2310001, Israel (Address o |
|
| March 3, 2016 |
EXHIBIT 12.2 CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO EXCHANGE ACT RULE 13A-14(A)/15D-14(A) AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Oren Bryan, certify that: 1. I have reviewed this annual report on Form 20-F of Enzymotec Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material f |
|
| March 3, 2016 |
EXHIBIT 13.1 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Enzymotec Ltd. (the “Company”) on Form 20-F for the period ended December 31, 2015, as filed with the Securities and Exchange Commission on the date hereof (the “Repo |
|
| March 3, 2016 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM EXHIBIT 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (File Nos. 333-193118 and 333-202839) of Enzymotec Ltd. of our report dated March 3, 2016, relating to the consolidated financial statements of Enzymotec Ltd., which appears in this Form 20-F. Tel-Aviv, Israel /s/ Kesselman & Kesselman |
|
| March 3, 2016 |
EXHIBIT 12.1 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO EXCHANGE ACT RULE 13A-14(A)/15D-14(A) AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Ariel Katz, certify that: 1. I have reviewed this annual report on Form 20-F of Enzymotec Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material f |
|
| March 3, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 20-F (Mark One) o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| March 1, 2016 |
March 1, 2016 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| February 22, 2016 |
zk1618104.htm February 22, 2016 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Jim B. Rosenberg Senior Assistant Chief Accountant, Office of Healthcare and Insurance Enzymotec Ltd. Form 20-F for the Year Ended December 31, 2014, Filed March 2, 2015 File No. 001-36073 Dear Mr. Rosenberg: On behalf of our client, Enzymotec |
|
| February 17, 2016 |
CORRECTING and REPLACING -- Enzymotec Ltd. Reports Fourth Quarter and Full Year 2015 Results exhibit99-1.htm Exhibit 99.1 CORRECTING and REPLACING - Enzymotec Ltd. Reports Fourth Quarter and Full Year 2015 Results In a release issued under the same headline earlier today by Enzymotec Ltd. (NASDAQ:ENZY), please note that in the Outlook for 2016 section, the first two bullets now read: · Net revenues, based on the proportionate consolidation method, of between $68 million and $78 million · |
|
| February 17, 2016 |
Enzymotec 6-K (Current Report of Foreign Issuer) zk1618076.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2016 Commission File Number: 001-36073 Enzymotec Ltd. (Translation of registrant?s name into English) Sagi 2000 Industrial Area P.O. Box 6 Migdal Ha?Emeq 2310001, Israel (Address of princ |
|
| February 17, 2016 |
exhibit99-1.htm Exhibit 99.1 Enzymotec Ltd. Reports Fourth Quarter and Full Year 2015 Results Fourth Quarter Non-GAAP Net Income* of $0.07 per Diluted Share Inclusive of $0.05 for Accelerated Growth Initiative Spend VAYA Pharma Generates Record Net Revenues of $2.3 Million in the Quarter and $8.5 Million in the Full Year MIGDAL HA'EMEQ, Israel, February 17, 2016 – Enzymotec Ltd. (NASDAQ: ENZY), a |
|
| February 17, 2016 |
Enzymotec 6-K/A (Current Report of Foreign Issuer) zk1618085.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K/A REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2016 Commission File Number: 001-36073 Enzymotec Ltd. (Translation of registrant?s name into English) Sagi 2000 Industrial Area P.O. Box 6 Migdal Ha?Emeq 2310001, Israel (Address of pri |
|
| February 12, 2016 |
Amendment No.2 to Schedule 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Enzymotec Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.01 per share (Title of Class of Securities) M4059L101 (CUSIP Number) December 31, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to |
|
| February 9, 2016 |
ENZY / Enzymotec Ltd. / XT Holdings Ltd. - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* Enzymotec Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.01 (Title of Class of Securities) M4059L101 (CUSIP Number) January 31, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| February 2, 2016 |
Enzymotec 6-K (Current Report of Foreign Issuer) zk1617930.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2016 Commission File Number: 001-36073 Enzymotec Ltd. (Translation of registrant?s name into English) Sagi 2000 Industrial Area P.O. Box 6 Migdal Ha?Emeq 2310001, Israel (Address of princ |
|
| February 2, 2016 |
exhibit99-1.htm Exhibit 99.1 Enzymotec Announces Positive Outcome in ICC Arbitration Award Arbitration tribunal rejects AAK?s requests for declaratory relief in their entirety Finds in accordance with Enzymotec?s position that the joint venture agreement may be terminated only through buy-sell procedure MIGDAL HA?EMEQ, ISRAEL, February 2, 2016?(GLOBENEWSWIRE)?Enzymotec Ltd. (NASDAQ: ENZY) (?Compan |
|
| January 7, 2016 |
January 7, 2016 Securities and Exchange Commission Division of Corporation Finance 110 F Street, N. |
|
| January 7, 2016 |
CORRESP 1 filename1.htm January 7, 2016 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Jim B. Rosenberg Senior Assistant Chief Accountant, Office of Healthcare and Insurance Enzymotec Ltd. Form 20-F for the Year Ended December 31, 2014, Filed March 2, 2015 File No. 001-36073 Dear Mr. Rosenberg: On behalf of our client, E |
|
| January 4, 2016 |
Enzymotec 6-K (Current Report of Foreign Issuer) SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of January 2016 Commission File Number: 001-36073 Enzymotec Ltd. (Translation of registrant?s name into English) Sagi 2000 Industrial Area P.O. Box 6 Migdal Ha?Emeq 2310001, Israel (Address of principal executive |
|
| January 4, 2016 |
exhibit99-1.htm Exhibit 99.1 Enzymotec Updates Automatic Extension of its Joint Venture Agreement with AAK until December 31, 2019 The International Court of Arbitration of the ICC has Extended the Time Limit for Rendering the Final Award until February 29, 2016 MIGDAL HA’EMEQ, ISRAEL, January 4, 2016—(GLOBENEWSWIRE)—Enzymotec Ltd. (NASDAQ: ENZY) (the “Company”), a developer, manufacturer and mark |
|
| December 4, 2015 |
Enzymotec 3G (Passive Acquisition of More Than 5% of Shares) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| November 20, 2015 |
exhibit99-1.htm Exhibit 99.1 Company Overview Ariel Katz | November 2015 Safe Harbor Statement • This presentation contains statements that, to the extent they are not recitations of historical fact, constitute "forward-looking statements." Forward-looking statements in this presentation are made pursuant to the safe harbor provisions contained in the Private Securities Litigation Reform Act of 19 |
|
| November 20, 2015 |
Enzymotec 6-K (Current Report of Foreign Issuer) SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2015 Commission File Number: 001-36073 Enzymotec Ltd. (Translation of registrant?s name into English) Sagi 2000 Industrial Area P.O. Box 6 Migdal Ha?Emeq 2310001, Israel (Address of principal executive |
|
| November 12, 2015 |
exhibit99-1.htm Exhibit 99.1 Enzymotec Ltd. Reports Third Quarter 2015 Results Earns non-GAAP $0.08 and GAAP $0.07 per Diluted Share and Generates $4.7 Million in Operating Cash Flow VAYA Pharma Generates Record Net Revenues of $2.2 Million MIGDAL HA'EMEQ, Israel, November 11, 2015 ? Enzymotec Ltd. (NASDAQ: ENZY), a developer, manufacturer and marketer of innovative bio-active lipid ingredients, t |
|
| November 12, 2015 |
Enzymotec 6-K (Current Report of Foreign Issuer) zk1517577.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2015 Commission File Number: 001-36073 Enzymotec Ltd. (Translation of registrant?s name into English) Sagi 2000 Industrial Area P.O. Box 6 Migdal Ha?Emeq 2310001, Israel (Address of princ |
|
| August 12, 2015 |
Enzymotec 6-K (Current Report of Foreign Issuer) zk1517217.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2015 Commission File Number: 001-36073 Enzymotec Ltd. (Translation of registrant?s name into English) Sagi 2000 Industrial Area P.O. Box 6 Migdal Ha?Emeq 2310001, Israel (Address of princip |
|
| August 12, 2015 |
exhibit99-1.htm Exhibit 99.1 Enzymotec Ltd. Reports Second Quarter 2015 Results Revenues and Adjusted EBITDA Increased for Fourth Consecutive Quarter Q2 Net Revenues Increased 49.5% Year-Over-Year; Q2 Net Income of $0.10 Per Diluted Share MIGDAL HA'EMEQ, Israel, August 12, 2015 ? Enzymotec Ltd. (Nasdaq: ENZY), a developer, manufacturer and marketer of innovative bio-active lipid ingredients, today |
|
| July 30, 2015 |
Enzymotec 6-K (Current Report of Foreign Issuer) zk1517119.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2015 Commission File Number: 001-36073 Enzymotec Ltd. (Translation of registrant?s name into English) Sagi 2000 Industrial Area P.O. Box 6 Migdal Ha?Emeq 2310001, Israel (Address of principal |
|
| June 25, 2015 |
ENZYMOTEC LTD. Sagi 2000 Industrial Area, P.O. Box 6, Migdal Ha’Emeq 2310001, Israel proxy.htm Exhibit 99.1 ENZYMOTEC LTD. Sagi 2000 Industrial Area, P.O. Box 6, Migdal Ha?Emeq 2310001, Israel Dear Enzymotec Ltd. Shareholders: We cordially invite you to attend the 2015 annual general meeting of shareholders, or the Meeting, of Enzymotec Ltd., or the Company, to be held at 5:00 pm (Israel time) on Wednesday, July 29, 2015, at our offices at Sagi 2000 Industrial Area, Migdal Ha?Emeq |
|
| June 25, 2015 |
Enzymotec 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2015 Commission File Number: 001-36073 ENZYMOTEC LTD. (Translation of registrant’s name into English) Sagi 2000 Industrial Area P.O. Box 6 Migdal Ha’Emeq 2310001, Israel (Address of principal |
|
| June 25, 2015 |
ENZYMOTEC LTD. PROXY FOR THE 2015 ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JULY 29, 2015 card.htm Exhibit 99.2 ENZYMOTEC LTD. PROXY FOR THE 2015 ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JULY 29, 2015 THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS The undersigned hereby constitutes and appoints Oren Bryan and Ron Mosberg, and each of them, the true and lawful attorneys, agents and proxies of the undersigned, with full power of substitution to each of them, to r |
|
| June 11, 2015 |
Enzymotec Ltd. Announces Annual General Meeting of Shareholders EX-99.1 2 exhibit99-1.htm EXHIBIT 99.1 Exhibit 99.1 Enzymotec Ltd. Announces Annual General Meeting of Shareholders MIGDAL HA’EMEQ, ISRAEL, June 11, 2015 (GLOBENEWSWIRE) Enzymotec Ltd. (NASDAQ: ENZY) (the “Company”), today announced that it will hold an Annual General Meeting of Shareholders on Wednesday, July 29, 2015. The record date for shareholders entitled to vote at the meeting is Friday, Ju |
|
| June 11, 2015 |
Enzymotec 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2015 Commission File Number: 001-36073 ENZYMOTEC LTD. (Translation of registrant?s name into English) Sagi 2000 Industrial Area P.O. Box 6 Migdal Ha?Emeq 2310001, Israel (Address of principal |
|
| June 8, 2015 |
ENZY / Enzymotec Ltd. / XT Holdings Ltd. - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) Enzymotec Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.01 (Title of Class of Securities) M4059L101 (CUSIP Number) December 31, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| May 7, 2015 |
exhibit99-1.htm Exhibit 99.1 Enzymotec Ltd. Reports First Quarter 2015 Unaudited Financial Results Earns $0.09 Per Diluted Share and Generates $3.1M in Operating Cash Flow MIGDAL HA'EMEQ, Israel, May 7, 2015 ? Enzymotec Ltd. (Nasdaq: ENZY), a developer, manufacturer and marketer of innovative bio-active lipid ingredients, today reported financial results for the first quarter ended March 31, 2015. |
|
| May 7, 2015 |
Enzymotec 6-K (Current Report of Foreign Issuer) zk1516726.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2015 Commission File Number: 001-36073 Enzymotec Ltd. (Translation of registrant?s name into English) Sagi 2000 Industrial Area P.O. Box 6 Migdal Ha?Emeq 2310001, Israel (Address of principal |
|
| March 18, 2015 |
As filed with the Securities and Exchange Commission on March 18, 2015 Registration No. |
|
| March 2, 2015 |
EXHIBIT 12.1 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO EXCHANGE ACT RULE 13A-14(A)/15D-14(A) AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Ariel Katz, certify that: 1. I have reviewed this annual report on Form 20-F of Enzymotec Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material f |
|
| March 2, 2015 |
ENZY / Enzymotec Ltd. 20-F - - 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 20-F (Mark One) o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2014 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| March 2, 2015 |
EXHIBIT 12.2 CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO EXCHANGE ACT RULE 13A-14(A)/15D-14(A) AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Oren Bryan, certify that: 1. I have reviewed this annual report on Form 20-F of Enzymotec Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material f |
|
| March 2, 2015 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM EXHIBIT 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statement on Form S-8 (File No. 333-193118) of Enzymotec Ltd. of our report dated March 2, 2015, relating to the consolidated financial statements of Enzymotec Ltd., which appears in this Form 20-F. Tel-Aviv, Israel /s/ Kesselman & Kesselman March 2, 2015 Ke |
|
| March 2, 2015 |
EXHIBIT 13.1 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Enzymotec Ltd. (the “Company”) on Form 20-F for the period ended December 31, 2014, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Ariel Katz, and I, Oren |
|
| February 18, 2015 |
ENZY / Enzymotec Ltd. 6-K - Current Report of Foreign Issuer - 6-K 6-K 1 zk1516313.htm 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2015 Commission File Number: 001-36073 Enzymotec Ltd. (Translation of registrant’s name into English) Sagi 2000 Industrial Area P.O. Box 6 Migdal Ha’Emeq 2310001, Israel (Addres |
|
| February 18, 2015 |
Enzymotec Ltd. Reports Fourth Quarter and Full Year 2014 Unaudited Financial Results Exhibit 99.1 Enzymotec Ltd. Reports Fourth Quarter and Full Year 2014 Unaudited Financial Results MIGDAL HA'EMEQ, Israel, February 18, 2015 – Enzymotec Ltd. (Nasdaq: ENZY), a developer, manufacturer and marketer of innovative bio-active lipid ingredients and medical foods, today reported its financial results for the fourth quarter and full year ended December 31, 2014. Fourth Quarter 2014 Financi |
|
| February 17, 2015 |
ENZY / Enzymotec Ltd. / PAULSON & CO. INC. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Enzymotec Ltd. (Name of Issuer) Ordinary Shares, par value NIS$0.01 per share (Title of Class of Securities) M4059L101 (CUSIP Number) December 31, 2014 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rul |
|
| February 12, 2015 |
ENZY / Enzymotec Ltd. / Galam Ltd. - SC 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 Enzymotec Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.01 per share (Title of Class of Securities) M4059L101 (CUSIP Number) February 12, 2015 (Date of Event Which R |
|
| February 12, 2015 |
Exhibit 1 February 11, 2015 Galam Ltd. Kibbutz Ma’anit 3785500 Israel Tel-Aviv, 67023 Israel Gentlemen, Pursuant to rule 13d-1(k)(1)(iii) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agrees that Galam Ltd. (“Galam”) may file as necessary on behalf of the undersigned with the Securities and Exchange Commission a Schedule 13G or a Schedule 13D and any ame |
|
| February 12, 2015 |
Exhibit 3 February 11, 2015 Galam Ltd. Kibbutz Ma’anit 3785500 Israel Tel-Aviv, 67023 Israel Gentlemen, Pursuant to rule 13d-1(k)(1)(iii) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agrees that Galam Ltd. (“Galam”) may file as necessary on behalf of the undersigned with the Securities and Exchange Commission a Schedule 13G or a Schedule 13D and any ame |
|
| February 12, 2015 |
ENZY / Enzymotec Ltd. 6-K - Current Report of Foreign Issuer - 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2015 Commission File Number: 001-36073 Enzymotec Ltd. (Translation of registrant’s name into English) Sagi 2000 Industrial Area P.O. Box 6 Migdal Ha’Emeq 2310001, Israel (Address of principal executive |
|
| February 12, 2015 |
Exhibit 2 February 11, 2015 Galam Ltd. Kibbutz Ma’anit 3785500 Israel Tel-Aviv, 67023 Israel Gentlemen, Pursuant to rule 13d-1(k)(1)(iii) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agrees that Galam Ltd. (“Galam”) may file as necessary on behalf of the undersigned with the Securities and Exchange Commission a Schedule 13G or a Schedule 13D and any ame |
|
| February 12, 2015 |
ENZY / Enzymotec Ltd. / Visium Asset Management, LP - SC 13G/A Passive Investment SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Enzymotec Ltd. (Name of Issuer) Ordinary Shares, NIS 0.01 per share (Title of Class of Securities) M4059L101 (CUSIP Number) December 31, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to w |
|
| January 22, 2015 |
ENZYMOTEC LTD. Sagi 2000 Industrial Area, P.O. Box 6, Migdal Ha’Emeq 2310001, Israel Exhibit 99.1 ENZYMOTEC LTD. Sagi 2000 Industrial Area, P.O. Box 6, Migdal Ha’Emeq 2310001, Israel Dear Enzymotec Ltd. Shareholders: We cordially invite you to attend an extraordinary general meeting, or the Meeting, of shareholders of Enzymotec Ltd., or the Company, to be held at 5:00 p.m. (Israel time) on Thursday, February 12, 2015, at our offices at Sagi 2000 Industrial Area, Migdal Ha’Emeq 231 |
|
| January 22, 2015 |
ENZY / Enzymotec Ltd. 6-K - Current Report of Foreign Issuer - 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of January 2015 Commission File Number: 001-36073 Enzymotec Ltd. (Translation of registrant’s name into English) Sagi 2000 Industrial Area P.O. Box 6 Migdal Ha’Emeq 2310001, Israel (Address of principal executive |
|
| January 22, 2015 |
Exhibit 99.2 ENZYMOTEC LTD. PROXY FOR AN EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON FEBRUARY 12, 2015 THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS The undersigned hereby constitutes and appoints Oren Bryan and Shiran Gazit and each of them, the true and lawful attorneys, agents and proxies of the undersigned, with full power of substitution to each of them, to repre |
|
| January 2, 2015 |
ENZY / Enzymotec Ltd. 6-K - Current Report of Foreign Issuer - 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of January 2015 Commission File Number: 001-36073 Enzymotec Ltd. (Translation of registrant’s name into English) Sagi 2000 Industrial Area P.O. Box 6 Migdal Ha’Emeq 2310001, Israel (Address of principal executive |
|
| January 2, 2015 |
Enzymotec Ltd. Announces an Extraordinary General Meeting of Shareholders EX-99 2 exhibit99-1.htm EXHIBIT 99.1 Exhibit 99.1 Enzymotec Ltd. Announces an Extraordinary General Meeting of Shareholders MIGDAL HA’EMEQ, ISRAEL, January 2, 2015—(GLOBENEWSWIRE)—Enzymotec Ltd. (NASDAQ: ENZY) (the “Company”) today announced that it will hold an Extraordinary General Meeting of Shareholders on Thursday, February 12, 2015. The record date for shareholders entitled to vote at the me |
|
| November 13, 2014 |
ENZY / Enzymotec Ltd. 6-K - Current Report of Foreign Issuer - 6-K 6-K 1 zk1415821.htm 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2014 Commission File Number: 001-36073 Enzymotec Ltd. (Translation of registrant’s name into English) Sagi 2000 Industrial Area P.O. Box 6 Migdal Ha’Emeq 2310001, Israel (Addres |
|
| November 13, 2014 |
Enzymotec Ltd. Reports Third Quarter 2014 Unaudited Financial Results Exhibit 99.1 Enzymotec Ltd. Reports Third Quarter 2014 Unaudited Financial Results MIGDAL HA'EMEQ, Israel, November 13, 2014 – Enzymotec Ltd. (Nasdaq: ENZY), a developer, manufacturer and marketer of innovative bio-active lipid ingredients, today reported its financial results for the third quarter ended September 30, 2014. Third Quarter 2014 Financial Highlights: · Third quarter net revenues (equ |
|
| October 1, 2014 |
ENZY / Enzymotec Ltd. 6-K - Current Report of Foreign Issuer - 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of October 2014 Commission File Number: 001-36073 Enzymotec Ltd. (Translation of registrant’s name into English) Sagi 2000 Industrial Area P.O. Box 6 Migdal Ha’Emeq 2310001, Israel (Address of principal executive |
|
| September 3, 2014 |
ENZYMOTEC LTD. PROXY FOR THE ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON SEPTEMBER 29, 2014 Exhibit 99.2 ENZYMOTEC LTD. PROXY FOR THE ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON SEPTEMBER 29, 2014 THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS The undersigned hereby constitutes and appoints Oren Bryan and Shiran Gazit and each of them, the true and lawful attorneys, agents and proxies of the undersigned, with full power of substitution to each of them, to represent |
|
| September 3, 2014 |
ENZY / Enzymotec Ltd. 6-K - Current Report of Foreign Issuer - 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2014 Commission File Number: 001-36073 Enzymotec Ltd. (Translation of registrant’s name into English) Sagi 2000 Industrial Area P.O. Box 6 Migdal Ha’Emeq 2310001, Israel (Address of principal executiv |
|
| September 3, 2014 |
ENZYMOTEC LTD. Sagi 2000 Industrial Area, P.O. Box 6, Migdal Ha’Emeq 2310001, Israel Exhibit 99.1 ENZYMOTEC LTD. Sagi 2000 Industrial Area, P.O. Box 6, Migdal Ha’Emeq 2310001, Israel Dear Enzymotec Ltd. Shareholders: We cordially invite you to attend the annual general meeting, or the Meeting, of shareholders of Enzymotec Ltd., or the Company, to be held at 5:00 p.m. (Israel time) on Monday, September 29, 2014, at our offices at Sagi 2000 Industrial Area, Migdal Ha’Emeq 2310001, I |
|
| August 25, 2014 |
ENZY / Enzymotec Ltd. 6-K - Current Report of Foreign Issuer - 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2014 Commission File Number: 001-36073 Enzymotec Ltd. (Translation of registrant’s name into English) Sagi 2000 Industrial Area P.O. Box 6 Migdal Ha’Emeq 2310001, Israel (Address of principal executive o |
|
| August 19, 2014 |
ENZY / Enzymotec Ltd. 6-K - Current Report of Foreign Issuer - 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2014 Commission File Number: 001-36073 Enzymotec Ltd. (Translation of registrant’s name into English) Sagi 2000 Industrial Area P.O. Box 6 Migdal Ha’Emeq 2310001, Israel (Address of principal executive o |
|
| August 19, 2014 |
Enzymotec Ltd. Announces an Annual General Meeting of Shareholders Exhibit 99.1 Enzymotec Ltd. Announces an Annual General Meeting of Shareholders MIGDAL HA’EMEQ, ISRAEL, August 19, 2014—(GLOBENEWSWIRE)—Enzymotec Ltd. (NASDAQ: ENZY) (the “Company”), today announced that it will hold an Annual General Meeting of Shareholders on Monday, September 29, 2014. The record date for shareholders entitled to vote at the meeting is Monday, August 25, 2014. The meeting is be |
|
| August 5, 2014 |
Enzymotec Ltd. Reports Second Quarter 2014 Unaudited Financial Results EX-99.1 2 exhibit99-1.htm EXHIBIT 99.1 Exhibit 99.1 Enzymotec Ltd. Reports Second Quarter 2014 Unaudited Financial Results MIGDAL HA'EMEQ, Israel, August 5, 2014 – Enzymotec Ltd. (Nasdaq: ENZY), a developer, manufacturer and marketer of innovative bio-active lipid ingredients, today reported financial results for the second quarter ended June 30, 2014. Second Quarter 2014 Financial Highlights, Com |
|
| August 5, 2014 |
ENZY / Enzymotec Ltd. 6-K - Current Report of Foreign Issuer - 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2014 Commission File Number: 001-36073 Enzymotec Ltd. (Translation of registrant’s name into English) Sagi 2000 Industrial Area P.O. Box 6 Migdal Ha’Emeq 2310001, Israel (Address of principal executive o |
|
| June 27, 2014 |
ENZY / Enzymotec Ltd. 6-K - Current Report of Foreign Issuer - 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2014 Commission File Number: 001-36073 Enzymotec Ltd. (Translation of registrant’s name into English) Sagi 2000 Industrial Area P.O. Box 6 Migdal Ha’Emeq 2310001, Israel (Address of principal executive off |
|
| May 30, 2014 |
ENZYMOTEC LTD. Sagi 2000 Industrial Area, P.O. Box 6, Migdal Ha’Emeq 2310001, Israel Exhibit 99.1 ENZYMOTEC LTD. Sagi 2000 Industrial Area, P.O. Box 6, Migdal Ha’Emeq 2310001, Israel Dear Enzymotec Ltd. Shareholders: We cordially invite you to attend an extraordinary general meeting, or the Meeting, of shareholders of Enzymotec Ltd., or the Company, to be held at 5:00 p.m. (Israel time) on Thursday, June 26, 2014, at our offices at Sagi 2000 Industrial Area, Migdal Ha’Emeq 2310001 |
|
| May 30, 2014 |
Exhibit 99.2 ENZYMOTEC LTD. PROXY FOR AN EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 26, 2014 THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS The undersigned hereby constitutes and appoints Oren Bryan and Shiran Gazit and each of them, the true and lawful attorneys, agents and proxies of the undersigned, with full power of substitution to each of them, to represent |
|
| May 30, 2014 |
Current Report of Foreign Issuer - 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2014 Commission File Number: 001-36073 Enzymotec Ltd. (Translation of registrant’s name into English) Sagi 2000 Industrial Area P.O. Box 6 Migdal Ha’Emeq 2310001, Israel (Address of principal executive offi |
|
| May 20, 2014 |
Current Report of Foreign Issuer - 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2014 Commission File Number: 001-36073 Enzymotec Ltd. (Translation of registrant’s name into English) Sagi 2000 Industrial Area P.O. Box 6 Migdal Ha’Emeq 2310001, Israel (Address of principal executive offi |
|
| May 20, 2014 |
Exhibit 99.1 Enzymotec Ltd. Announces an Extraordinary General Meeting of Shareholders to Approve its Compensation Policy MIGDAL HA’EMEQ, ISRAEL, May 20, 2014—(GLOBENEWSWIRE)—Enzymotec Ltd. (NASDAQ: ENZY) (the “Company”), today announced that it will hold an Extraordinary General Meeting of Shareholders on Thursday, June 26, 2014. The record date for shareholders entitled to vote at the meeting is |
|
| May 14, 2014 |
Exhibit 99.1 Enzymotec Ltd. Reports First Quarter 2014 Unaudited Financial Results Net Revenues Increased 29% to $17.9 Million Net Income Increased 118% to $5.1 Million, or $0.22 Per Share (Quarterly Non-GAAP Net Income Increased 135% to $5.6 Million, or $0.24 Per Share) MIGDAL HA'EMEQ, Israel, May 14, 2014 – Enzymotec Ltd. (Nasdaq: ENZY), a developer, manufacturer and marketer of innovative bio-a |
|
| May 14, 2014 |
Current Report of Foreign Issuer - 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2014 Commission File Number: 001-36073 Enzymotec Ltd. (Translation of registrant’s name into English) Sagi 2000 Industrial Area P.O. Box 6 Migdal Ha’Emeq 2310001, Israel (Address of principal executive offi |
|
| March 10, 2014 |
ENZY / Enzymotec Ltd. / PAULSON & CO. INC. Passive Investment SC 13G/A 1 formsc13ga-enzymotec.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Enzymotec Ltd. (Name of Issuer) Ordinary Shares, par value NIS$0.01 per share (Title of Class of Securities) M4059L101 (CUSIP Number) February 28, 2014 (Date of Event which Requires Filing of this Statement) Check the |
|
| March 10, 2014 |
ENZY / Enzymotec Ltd. / Visium Asset Management, LP - SCHEDULE 13G Passive Investment Schedule 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Enzymotec, Ltd. (Name of Issuer) Common Stock, $0.01 per share (Title of Class of Securities) M4059L101 (CUSIP Number) February 28, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule i |
|
| March 3, 2014 |
Filed Pursuant to Rule 424(b)(1) Registration Nos. 333-193923 and 333-194240 P R O S P E C T U S 4,698,857 Shares Enzymotec Ltd. Ordinary Shares The selling shareholders named in this prospectus are selling 4,698,857 of our ordinary shares. We will not receive any proceeds from the sale of ordinary shares by the selling shareholders. Our ordinary shares are listed on the NASDAQ Global Select Marke |
|
| February 27, 2014 |
F-1MEF 1 v370068f1mef.htm F-1MEF As filed with the Securities and Exchange Commission on February 27, 2014 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ENZYMOTEC LTD. (Exact Name of Registrant as Specified in its Charter) State of Israel 2833 Not Applicable (State or Other Jurisdiction |
|
| February 24, 2014 |
Exhibit 1.1 ENZYMOTEC LTD. (A company organized under the laws of the State of Israel) [·] Ordinary Shares UNDERWRITING AGREEMENT Dated: [·], 2014 ENZYMOTEC LTD. (A company organized under the laws of the State of Israel) [·] Ordinary Shares UNDERWRITING AGREEMENT [·], 2014 Merrill Lynch, Pierce, Fenner & Smith Incorporated Jefferies LLC as Representatives of the several Underwriters c/o Merrill L |
|
| February 24, 2014 |
As filed with the Securities and Exchange Commission on February 24, 2014 Registration No. |
|
| February 18, 2014 |
As filed with the Securities and Exchange Commission on February 18, 2014 Registration No. |
|
| February 18, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 20-F/A (Mark One) o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2013 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES E |
|
| February 14, 2014 |
ENZY / Enzymotec Ltd. / PAULSON & CO. INC. Passive Investment SC 13G 1 formsc13g-enzymotec.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Enzymotec Ltd. (Name of Issuer) Ordinary Shares, par value NIS$0.01 per share (Title of Class of Securities) M4059L101 (CUSIP Number) December 31, 2013 (Date of Event which Requires Filing of this Statement) Check the appr |
|
| February 13, 2014 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM EXHIBIT 14.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statement on Form S-8 (File No. 333-193118) of Enzymotec Ltd. of our report dated February 13, 2014, relating to the consolidated financial statements of Enzymotec Ltd., which appears in this Form 20-F. Tel-Aviv, Israel /s/ Kesselman & Kesselman February 13, |
|
| February 13, 2014 |
As filed with the Securities and Exchange Commission on February 13, 2014 Registration No. |
|
| February 13, 2014 |
EXHIBIT 12.2 CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO EXCHANGE ACT RULE 13A-14(A)/15D-14(A) AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Oren Bryan, certify that: 1. I have reviewed this annual report on Form 20-F of Enzymotec Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material f |
|
| February 13, 2014 |
Enzymotec Ltd. Files Registration Statement for Proposed Secondary Offering Exhibit 99.2 Enzymotec Ltd. Files Registration Statement for Proposed Secondary Offering MIGDAL HA'EMEQ, Israel, February 13, 2014 – Enzymotec Ltd. (Nasdaq: ENZY) (the “Company”) today announced that it has filed a registration statement on Form F-1 with the Securities and Exchange Commission for a proposed secondary public offering of 4,000,000 of its ordinary shares. The underwriters will have a |
|
| February 13, 2014 |
Current Report of Foreign Issuer - 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2014 Commission File Number: 001-36073 Enzymotec Ltd. (Translation of registrant’s name into English) Sagi 2000 Industrial Area P.O. Box 6 Migdal Ha’Emeq 2310001, Israel (Address of principal executive |
|
| February 13, 2014 |
EXHIBIT 12.1 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO EXCHANGE ACT RULE 13A-14(A)/15D-14(A) AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Ariel Katz, certify that: 1. I have reviewed this annual report on Form 20-F of Enzymotec Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material f |
|
| February 13, 2014 |
EXHIBIT 13.1 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Enzymotec Ltd. (the “Company”) on Form 20-F for the period ended December 31, 2013, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Ariel Katz, and I, Oren |
|
| February 13, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 20-F (Mark One) ¨ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2013 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| February 13, 2014 |
Exhibit 99.1 Enzymotec Ltd. Reports Fourth Quarter and Full Year 2013 Unaudited Financial Results Quarterly Net Revenues Increased 59% to $18.5 Million and Annual Net Revenues Increased 72% to $65.0 Million Quarterly Net Income Increased 57% to $3.4 Million, or $0.15 Per Share, and Annual Net Income Increased 138% to $11.4 Million, or $0.53 per share (Quarterly Non-GAAP Net Income Increased 146% t |
|
| February 12, 2014 |
ENZY / Enzymotec Ltd. / XT Holdings Ltd. - SC 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 Enzymotec Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.01 (Title of Class of Securities) M4059L101 (CUSIP Number) December 31, 2013 (Date of Event Which Requires Fi |
|
| February 12, 2014 |
Exhibit 1 JOINT FILING AGREEMENT The undersigned parties hereby agree that this Statement on Schedule 13G filed herewith, and any amendments thereto filed hereafter by any of the undersigned parties, relating to the ordinary shares, par value NIS 0. |
|
| February 5, 2014 |
Exhibit 3 February 3, 2014 Galam Ltd. Kibbutz Ma’anit 3785500 Israel Tel-Aviv, 67023 Israel Gentlemen, Pursuant to rule 13d-1(k)(1)(iii) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agrees that Galam Ltd. (“Galam”) may file as necessary on behalf of the undersigned with the Securities and Exchange Commission a Schedule 13G or a Schedule 13D and any amen |
|
| February 5, 2014 |
Exhibit 1 February 3, 2014 Galam Ltd. Kibbutz Ma’anit 3785500 Israel Tel-Aviv, 67023 Israel Gentlemen, Pursuant to rule 13d-1(k)(1)(iii) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agrees that Galam Ltd. (“Galam”) may file as necessary on behalf of the undersigned with the Securities and Exchange Commission a Schedule 13G or a Schedule 13D and any amen |
|
| February 5, 2014 |
ENZY / Enzymotec Ltd. / Galam Ltd. - SC 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 Enzymotec Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.01 per share (Title of Class of Securities) M4059L101 (CUSIP Number) February 5, 2014 (Date of Event Which Re |
|
| February 5, 2014 |
EX-99 3 exhibit2.htm EXHIBIT 2 Exhibit 2 February 3, 2014 Galam Ltd. Kibbutz Ma’anit 3785500 Israel Tel-Aviv, 67023 Israel Gentlemen, Pursuant to rule 13d-1(k)(1)(iii) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agrees that Galam Ltd. (“Galam”) may file as necessary on behalf of the undersigned with the Securities and Exchange Commission a Schedule 13G |
|
| January 27, 2014 |
EX-99 2 exhibit1.htm EXHIBIT 1 Exhibit 1 2014–01–27 874/4 By : Mail To: M. M. C. II - MILLENNIUM MATERIALS II FUND MANAGEMENT COMPANY LTD. 40, Einstein St. Tel Aviv 69101 Israel Re: Subject: M. M. C. II - MILLENNIUM MATERIALS II FUND MANAGEMENT COMPANY LTD. (“the Company”) - Signatory rights As legal advisors to the Company, we hereby certify that in accordance with the resolutions of the Board o |
|
| January 27, 2014 |
ENZY / Enzymotec Ltd. / Millennium Materials Technologies Fund II L.P - SC 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 Enzymotec Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.01 per share (Title of Class of Securities) M4059L101 (CUSIP Number) December 31, 2013 (Date of Event Which R |
|
| December 30, 2013 |
As filed with the Securities and Exchange Commission on December 30, 2013 Registration No. |
|
| December 20, 2013 |
Current Report of Foreign Issuer - 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2013 Commission File Number: 001-36073 Enzymotec Ltd. (Translation of registrant’s name into English) Sagi 2000 Industrial Area P.O. Box 6 Migdal Ha’Emeq 2310001, Israel (Address of principal executive |
|
| November 18, 2013 |
Current Report of Foreign Issuer - 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2013 Commission File Number: 001-36073 Enzymotec Ltd. (Translation of registrant’s name into English) Sagi 2000 Industrial Area P.O. Box 6 Migdal Ha’Emeq 2310001, Israel (Address of principal executive |
|
| November 18, 2013 |
Exhibit 99.2 ENZYMOTEC LTD. PROXY FOR AN EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON DECEMBER 19, 2013 THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS The undersigned hereby constitutes and appoints Oren Bryan and Shiran Gazit and each of them, the true and lawful attorneys, agents and proxies of the undersigned, with full power of substitution to each of them, to repre |
|
| November 18, 2013 |
Exhibit 99.1 ENZYMOTEC LTD. Sagi 2000 Industrial Area, P.O. Box 6, Migdal Ha’Emeq 2310001, Israel November 18, 2013 NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON DECEMBER 19, 2013 Dear Enzymotec Ltd. Shareholders: We cordially invite you to attend an Extraordinary General Meeting of shareholders of Enzymotec Ltd., or the Company, to be held at 5:00 p.m. (Israel time) on Thu |
|
| November 12, 2013 |
Current Report of Foreign Issuer - 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2013 Commission File Number: 001-36073 Enzymotec Ltd. (Translation of registrant’s name into English) Sagi 2000 Industrial Area P.O. Box 6 Migdal Ha’Emeq 2310001, Israel (Address of principal executive |
|
| November 12, 2013 |
Exhibit 99.1 ENZYMOTEC REPORTS RECORD 2013 THIRD QUARTER RESULTS Quarterly net revenues increased 66.3% to $17.8 million Net income increased 87.5% to $3.3 million Successfully completed an IPO with net proceeds of $63.5 million MIGDAL HA'EMEQ, Israel, November 11, 2013 - Enzymotec Ltd. (NasdaqGS: ENZY), reported today its financial results for the third quarter and nine months ended September 30, |
|
| November 8, 2013 |
Current Report of Foreign Issuer - 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2013 Commission File Number: 001-36073 Enzymotec Ltd. (Translation of registrant’s name into English) Sagi 2000 Industrial Area P.O. Box 6 Migdal Ha’Emeq 2310001, Israel (Address of principal executive |
|
| November 8, 2013 |
Exhibit 99.1 PRESS RELEASE Enzymotec Announces Extraordinary General Meeting of Shareholders for Ratification of Appointment of External Directors and Certain Director Compensation Matters MIGDAL HA’EMEQ, ISRAEL, November 8, 2013—(GLOBENEWSWIRE)—Enzymotec Ltd. (NASDAQ: ENZY) (the “Company”), today announced that it will hold an Extraordinary General Meeting of Shareholders on Thursday, December 19 |
|
| September 30, 2013 |
Filed Pursuant to Rule 424(b)(4) Registration No. 333-190781 P R O S P E C T U S 4,412,000 Shares Enzymotec Ltd. Ordinary Shares This is Enzymotec Ltd.’s initial public offering. We are selling 4,412,000 of our ordinary shares. The initial public offering price is $14.00 per share. Prior to this offering, there has been no public market for our ordinary shares. Our ordinary shares have been approv |
|
| September 27, 2013 |
Exhibit 10.3 SHARE PURCHASE AGREEMENT This SHARE PURCHASE AGREEMENT (this “Agreement”) is made as of the 27th day of September 2011, by and among Enzymotec Ltd., an Israeli company (Reg. No. 51-260924-9) with principal offices at P.O. Box 6, Migdal Ha'Emek 23106, Israel (the “Company”) and the Investors listed under Schedule I hereto (each, an “Investor”, and collectively, the “Investors”). RECITA |
|
| September 27, 2013 |
FORM OF INDEMNIFICATION AGREEMENT Exhibit 10.16 FORM OF INDEMNIFICATION AGREEMENT THIS INDEMNIFICATION AGREEMENT (the “Agreement”), dated as of [], 2013, is entered into by and between Enzymotec Ltd., an Israeli company whose address is Sagi 2000 Industrial Area, Migdal Ha’Emeq 2310001, Israel (the “Company”), and [], the/a [insert position of the officer] of the Company whose address is [] (the “Indemnitee”). WHEREAS, Indemnitee |
|
| September 27, 2013 |
AMENDMENTS TO CURRENT ARTICLES OF ASSOCIATION Exhibit 3.4 Extract showing changes to the Third Amended and Restated Articles of Association, approved by the shareholders on August 8, 2013 AMENDMENTS TO CURRENT ARTICLES OF ASSOCIATION 1. The definition of "Galam" in Article 1 of the Articles shall be amended and replaced in its entirety with the following, to read as follows: “Galam shall mean Galam Ltd. and/or Galam Management and Marketing A |
|
| September 27, 2013 |
Exhibit 3.3 Changes to the Third Amended and Restated Articles of Association, approved by the shareholders on April 17, 2013 “The Board of Directors 80. The number of members of the Board of Directors of the Company shall be not less than one (1) and not more than ten (10) members. 80.1 Subject to the provisions of Article 80.9 below, the Board of Directors (and of any subsidiaries of the Company |
|
| September 27, 2013 |
AMENDMENT & JOINDER TO SHARE PURCHASE AGREEMENT EX-10.8 11 v356029ex10-8.htm EXHIBIT 10.8 Exhibit 10.8 AMENDMENT & JOINDER TO SHARE PURCHASE AGREEMENT This Amendment & Joinder Agreement (this “Joinder Agreement”) to the Share Purchase Agreement dated September 27, 2011, which is attached hereto as Exhibit A (the “SPA”), is made and entered into on March 8, 2012 by and among: (i) Enzymotec Ltd., an Israeli company (the "Company"), (ii) Vintage V |
|
| September 27, 2013 |
Exhibit 10.21 English summary of a Loan Agreement dated as of September 9, 2009, by and between Israel Discount Bank (the "Bank") and Enzymotec Ltd. (the "Company") (the "Loan Agreement"). · Subject Matter of Agreement: Provision of a US $5,600,000 loan granted to the Company by the Bank (the "Loan") for purposes of investment by the Company in its factory (real estate, infrastructure and mechaniz |
|
| September 27, 2013 |
ENZYMOTEC LTD. 2003 ISRAELI SHARE OPTION PLAN A. NAME AND PURPOSE Exhibit 10.13 ENZYMOTEC LTD. 2003 ISRAELI SHARE OPTION PLAN A. NAME AND PURPOSE 1. Name: This plan, as amended from time to time, shall be known as Enzymotec Ltd. 2003 Israeli Share Option Plan (the "Plan"). 2. Purpose: 2.1 The purpose and intent of the Plan is to provide incentives, including but not limited to employees, directors, consultants and service providers of Enzymotec Ltd. and its Subs |
|
| September 27, 2013 |
ENZYMOTEC LTD. 2012 U.S. Addendum Exhibit 10.14 ENZYMOTEC LTD. 2012 U.S. Addendum 1. Purpose of the Addendum: This Addendum shall form an integral part of the 2003 Israeli Share Option Plan (the “Plan”) of Enzymotec Ltd. (the "Company"), and it shall apply only to Employees and Service Providers who are (i) deemed residents of the United States for the purpose of U.S. tax laws; and (ii) employed by the Company or any of its U.S. S |
|
| September 27, 2013 |
Subsidiaries of Enzymotec Ltd. Exhibit 21.1 Subsidiaries of Enzymotec Ltd. Name of Subsidiary Jurisdiction of Organization Ownership Interest Enzymotec USA, Inc. Delaware 100% VAYA Pharma, Inc. Delaware 100% Advanced Lipids AB Sweden 50% |
|
| September 27, 2013 |
AMENDMENT TO MEMORANDUM OF UNDERSTANDING Exhibit 10.20 AMENDMENT TO MEMORANDUM OF UNDERSTANDING THIS AMENDMENT TO THE MEMORANDUM OF UNDERSTANDING (the “Amendment”) is made and entered into as of the 14th day of June, 2013, by and between Antarctic Sea Fisheries, S.A., a corporation organized and existing under the laws of Chile, tax payer N° 96.539.160-6, represented by Mr. Enrique Le Dantec B., Chilean tax payer N° 8.882.183-1, and by M |
|
| September 27, 2013 |
Exhibit 99.2 Consent of Director Nominee Enzymotec Ltd. (the “Company”) has filed a Registration Statement on Form F-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), in connection with the proposed initial public offering of its ordinary shares. In connection therewith, I hereby consent, pursuant to Rule 438 of the Securities Act, t |
|
| September 27, 2013 |
Form of Joinder to Share Purchase Agreement Exhibit 10.7 Form of Joinder to Share Purchase Agreement This Joinder Agreement (this “Joinder Agreement”) is made as of the date written below by [ ] (the “Joining Party”) in accordance with Sections 4.3 and 4.4 of that certain the Share Purchase Agreement dated September 27, 2011 (the “Investment Agreement”) by and among Enzymotec Ltd. and investors named therein, as the same may be amended from |
|
| September 27, 2013 |
Exhibit 3.2 Changes to the Third Amended and Restated Articles of Association, approved by the shareholders on May 29, 2012 "The term “Permitted Transferee” shall mean: (i) in the case of an individual Shareholder - a spouse, parents, child, brother, sister or trustee of the shareholder (or his/her spouse) and any corporate entity which is controlled by him/her; (ii) in the case of any incorporate |
|
| September 27, 2013 |
Joinder to Share Purchase Agreement Exhibit 10.6 Joinder to Share Purchase Agreement This Joinder Agreement (this “Joinder Agreement”) is made as of the date written below by Israel Secondary Investments (BVI) L.P. (the “Joining Party”) in accordance with Sections 4.3 and 4.4 of that certain the Share Purchase Agreement dated September 27, 2011 (the “Investment Agreement”) by and among Enzymotec Ltd. and investors named therein, as |
|
| September 27, 2013 |
Exhibit 10.24 English summary of the August 7, 2013 Amendment No. 1 to the May 1, 2012 and September 9, 2012 Line of Credit Agreements (the "First Agreement" and "Second Agreement", respectively and the "Agreements" collectively), by and between Israel Discount Bank (the "Bank") and Enzymotec Ltd. (the "Company") (the "Amendment"). · Drawdown Period: the period in which the Company may withdraw lo |
|
| September 27, 2013 |
Joinder to Share Purchase Agreement Exhibit 10.5 Joinder to Share Purchase Agreement This Joinder Agreement (this “Joinder Agreement”) is made as of the date written below by Israel Secondary Fund (ISR) L.P. (the “Joining Party”) in accordance with Sections 4.3 and 4.4 of that certain the Share Purchase Agreement dated September 27, 2011 (the “Investment Agreement”) by and among Enzymotec Ltd. and investors named therein, as the sam |
|
| September 27, 2013 |
Exhibit 10.22 English summary of the Line of Credit Agreement dated as of May 1, 2012, by and between Israel Discount Bank (the "Bank") and Enzymotec Ltd. (the "Company") (the "Credit Line Agreement"). · Subject Matter of Agreement: Provision of a credit line given to the Company by the Bank of up to a maximum amount equal to the lower of U.S $7,600,000 or 20% of the Company’s consolidated net rev |
|
| September 27, 2013 |
MEMORANDUM OF UNDERSTANDING BY AND AMONG ANTARCTIC SEA FISHERIES S.A. ENZYMOTEC LTD. Exhibit 10.19 MEMORANDUM OF UNDERSTANDING BY AND AMONG ANTARCTIC SEA FISHERIES S.A. AND ENZYMOTEC LTD. This Memorandum of Understanding is entered between /i/. ANTARCTIC SEA FISHERIES S.A., a corporation organized and existing under the laws of Chile, tax payer N° 96.539.160-6, represented by Mr. Enrique Le Dantec B., Chilean tax payer N° 8.882.183-1, and by Mr. Mario Tapia E., Chilean tax payer N |
|
| September 27, 2013 |
Re: Amendment to Manufacture and Supply Agreement EX-10.18 17 v356029ex10-18.htm EXHIBIT 10.18 Exhibit 10.18 2/12/12 To: Mr. Avtar Singh/Mr. Jain Parkash PUNJAB Chemicals and Corp Protection Ltd. (Pharma Div.-Alpha Drug) Village – Kolimajra and Samalheri, P.O.- Lalru Distt. SAS Nagar Mohali, Punjab - 140501 Re: Amendment to Manufacture and Supply Agreement Enzymotec Ltd., and PUNJAB Chemicals and Corp Protection Ltd. (Pharma Div.-Alpha Drug), are |
|
| September 27, 2013 |
As filed with the Securities and Exchange Commission on September 27, 2013. Registration No. 333-190781 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Post-Effective Amendment No. 1 to FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ENZYMOTEC LTD. (Exact Name of Registrant as Specified in its Charter) State of Israel 2833 Not Applicable (State or Other Jur |
|
| September 27, 2013 |
Exhibit 99.1 Consent of Director Nominee Enzymotec Ltd. (the “Company”) has filed a Registration Statement on Form F-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), in connection with the proposed initial public offering of its ordinary shares. In connection therewith, I hereby consent, pursuant to Rule 438 of the Securities Act, t |
|
| September 27, 2013 |
ENZYMOTEC LTD. Co. No. 51-260924-9 EMPLOYEE SHARE OPTION PLAN (1999) A. NAME AND PURPOSE Exhibit 10.12 ENZYMOTEC LTD. Co. No. 51-260924-9 EMPLOYEE SHARE OPTION PLAN (1999) A. NAME AND PURPOSE 1. Name: This plan, as amended from time to time, shall be known as the Enzymotec Ltd. Employee Share Option Plan (1999) (the "Plan"). 2. Purpose: The purpose and intent of the Plan is to provide incentives to employees of Enzymotec Ltd. (the "Company"), by providing them with opportunities to pu |
|
| September 27, 2013 |
Joinder to Share Purchase Agreement Exhibit 10.4 Joinder to Share Purchase Agreement This Joinder Agreement (this “Joinder Agreement”) is made as of the date written below by Glenrock Israel Ltd. (the “Joining Party”) in accordance with Section 4.3 of that certain the Share Purchase Agreement dated September 27, 2011 (the “Investment Agreement”) by and among Enzymotec Ltd. and investors named therein, as the same may be amended from |
|
| September 27, 2013 |
Exhibit 3.1 The Companies Law 5759 - 1999 A Company Limited by Shares Third Amended and Restated Articles of Association of Enzymotec Ltd. Preliminary 1. In these Articles of Association, unless the context otherwise requires: Arancia Shall mean Arancia International, Inc. Articles Shall mean these Third Amended and Restated Articles of Association of Enzymotec Ltd., as amended from time to time. |
|
| September 27, 2013 |
Exhibit 10.23 English summary of the Line of Credit Agreement dated as of September 9, 2012, by and between Israel Discount Bank (the "Bank") and Enzymotec Ltd. (the "Company") (the "Credit Line Agreement"). · Subject Matter of Agreement: Provision of a credit line given to the Company by the Bank of up to a maximum amount of $U.S 3,750,000 (the "Credit Line"). · Terms of the Credit Line Agreement |
|
| September 27, 2013 |
MANUFACTURE AND SUPPLY AGREEMENT EX-10.17 16 v356029ex10-17.htm EXHIBIT 10.17 Exhibit 10.17 MANUFACTURE AND SUPPLY AGREEMENT This Manufacture and Supply Agreement is made and entered into as of the 15 day of February, 2009 (the "Effective Date"), by and between Enzymotec Ltd., an Israeli company (“Enzymotec”) and PUNJAB Chemicals and Corp Protection Ltd., an Indian company (“Manufacturer”). Enzymotec and Manufacturer are sometime |
|
| September 24, 2013 |
Global Markets & Investment Banking One Bryant Park – 8th Floor New York, New York 10036 646-855-6780 September 24, 2013 Securities and Exchange Commission 100 F Street, N. |
|
| September 24, 2013 |
September 24, 2013 Securities and Exchange Commission Division of Corporation Finance 110 F Street, N. |
|
| September 24, 2013 |
EX-10.9 4 v355596ex10-9.htm EXHIBIT 10.9 Exhibit 10.9 ENZYMOTEC LTD. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT DATED SEPTEMBER 22, 2013 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT This AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (“Agreement”) is made as of the 22nd of September, 2013, by and among Enzymotec Ltd., an Israeli company (the “Company”) and each of the investors listed |
|
| September 24, 2013 |
As filed with the Securities and Exchange Commission on September 24, 2013. Registration No. 333-190781 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No.2 to FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ENZYMOTEC LTD. (Exact Name of Registrant as Specified in its Charter) State of Israel 2833 Not Applicable (State or Other Jurisdiction of Inc |
|
| September 24, 2013 |
ARTICLES OF ASSOCIATION ENZYMOTEC LTD. A COMPANY LIMITED BY SHARES UNDER THE COMPANIES LAW - 1999 Exhibit 3.6 ARTICLES OF ASSOCIATION OF ENZYMOTEC LTD. A COMPANY LIMITED BY SHARES UNDER THE COMPANIES LAW - 1999 1. INTERPRETATION. 1.1. In these Articles, unless the context requires another meaning the words in the first column of the following table shall have the meanings set opposite them in the second column: “Articles” these Articles of Association, as amended from time to time by a Resolut |
|
| September 17, 2013 |
8-A12B 1 v3551628a12b.htm 8-A12B As filed with the Securities and Exchange Commission on September 17, 2013 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Enzymotec Ltd. (Exact name of registrant as specified in charter) State of Israel (State |
|
| September 16, 2013 |
Exhibit 10.25 English summary of the Amendments and Clarifications to the Debentures Executed for the Benefit of Israeli Discount Bank (the "Bank") dated September 15, 2013 Below is a summary of the bank letter dated September 15, 2013 (the "Letter") which modifies certain provisions of the following debentures and pledges executed by Enzymotec Ltd. (the "Company") for the benefit of the Bank (the |
